Daxor’s BVA technology gains traction at cardiology event

OAK RIDGE, TN - Daxor Corporation (NASDAQ:DXR), known for its blood volume measurement technology and trading at $8.12 per share, reported significant interest in its Blood Volume Analyzer (BVA-100®) at the American College of Cardiology’s 74th Annual Scientific Session and Expo in Chicago. According to InvestingPro data, analysts have set price targets between $22 and $25, suggesting significant upside potential despite the company’s recent revenue challenges. The conference, which took place from March 29-31, featured a presentation by Dr. Marat Fudim of Duke University Health, highlighting the advantages of BVA over traditional pressure-based assessments for heart failure patients.

The presentation, titled "When Pressure ≠ Volume: Understanding Complex Hemodynamic Situations and Pitfalls," drew over 400 clinicians and emphasized the limitations of pressure-based assessments in accurately determining a patient’s volume status. Dr. Fudim’s research supports the notion that volume management is more critical than pressure management in treating heart failure. While the company maintains a 100% gross profit margin according to InvestingPro data, analysts anticipate a sales decline in the current year, making the company’s market positioning crucial.

Additionally, new research from Duke University Medical Center was showcased, revealing that commonly used proxy markers for volume care, such as urine output, weight change, and biomarkers like CA-125 and NT-proBNP, did not correlate with intravascular volume changes during heart failure hospitalization. This finding underscores the need for precision in managing congestion in heart failure, which BVA aims to address.

John L. Jefferies, MD, MBA, MPH, Chief Medical Officer at Daxor, stated that traditional methods often mislead by relying on indirect markers that do not accurately reflect true blood volume status. He asserted that BVA provides the clarity needed for clinicians to optimize treatment and improve patient outcomes.

Daxor’s BVA-100® is the only FDA-cleared diagnostic blood test that quantifies blood volume status and composition against patient-specific norms. The technology has been used in over 65,000 tests across the U.S., contributing to improved hospital performance metrics, including reduced mortality and readmissions in heart failure and critical care.

The company continues to support ongoing trials in heart failure treatment with NIH backing and is developing analyzers to enhance combat casualty care for the U.S. Department of Defense. Daxor’s mission is to advance healthcare through optimal fluid management with blood volume analysis. With a beta of -0.53, the stock often moves counter to market trends, potentially offering portfolio diversification benefits. For deeper insights into Daxor’s growth potential and comprehensive analysis, investors can access the detailed Pro Research Report available on InvestingPro, which provides expert analysis and actionable intelligence for informed investment decisions.

This report is based on a press release statement from Daxor Corporation.

In other recent news, Daxor Corporation reported a remarkable 116.5% increase in revenue for the fourth quarter of 2024 compared to the previous year. The company also reached a significant milestone by achieving cash flow breakeven in the first quarter of 2025. This financial growth is attributed to the company’s strategic market expansion and innovative product developments. Furthermore, Daxor is planning to resubmit its next-generation blood volume analyzer for FDA approval, aiming for a 510(k) clearance, which could further bolster its market presence. Additionally, the company has expanded its market reach with new accounts and increased sales of its diagnostic kits. Analysts have shown interest in Daxor’s financial investments and strategies to maintain cash flow positivity, indicating a positive outlook for the company’s future developments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.